← Back to Search

Dietary Supplement

Faba Bean-Enriched Foods for Diabetes and Obesity

N/A
Waitlist Available
Led By Harvey G Anderson, PhD
Research Sponsored by University of Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No metabolic disease
Male
Timeline
Screening 3 weeks
Treatment Varies
Follow Up starting at the beginning of each session (0 minutes, before consumption of treatment) and every 15 - 30 minutes up to 200 minutes (time of completion of each session)
Awards & highlights

Study Summary

This trial found that adding faba bean to crackers or pasta may reduce blood glucose and food intake.

Who is the study for?
This trial is for non-smoking men aged 18-30 with a BMI between 20 and 25, who do not have metabolic diseases or intolerances to treatments. It's not suitable for those on appetite-modifying meds, with restrictive eating habits, who skip breakfast, or are over/underweight.Check my eligibility
What is being tested?
The study tests if crackers/pasta enriched with faba bean components (protein concentrate/isolate, flour, starch) can lower blood sugar response and reduce food intake compared to products without these ingredients.See study design
What are the potential side effects?
Potential side effects may include digestive discomfort due to the high fiber content in faba beans. However, since this is a food-based intervention rather than medication, severe side effects are unlikely.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I do not have a metabolic disease.
Select...
I am male.
Select...
I am between 18 and 30 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~starting at the beginning of each session (0 minutes, before consumption of treatment) and every 15 - 30 minutes up to 200 minutes (time of completion of each session)
This trial's timeline: 3 weeks for screening, Varies for treatment, and starting at the beginning of each session (0 minutes, before consumption of treatment) and every 15 - 30 minutes up to 200 minutes (time of completion of each session) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in blood glucose levels
Change in gut hormone levels measured in the blood
Secondary outcome measures
Ad libitum food (pizza meal) intake as measured by the amount of pizza (in grams) consumed during the 20 minute period
Subjective appetite

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: Faba bean starchExperimental Treatment1 Intervention
Crackers/pasta with added faba bean starch
Group II: Faba bean protein isolateExperimental Treatment1 Intervention
Crackers/pasta with added faba bean protein isolate
Group III: Faba bean protein concentrateExperimental Treatment1 Intervention
Crackers/pasta with added faba bean protein concentrate
Group IV: Faba bean flourExperimental Treatment1 Intervention
Crackers/pasta with added faba bean flour
Group V: ControlActive Control1 Intervention
Crackers/pasta with no faba bean fraction

Find a Location

Who is running the clinical trial?

University of TorontoLead Sponsor
689 Previous Clinical Trials
1,018,583 Total Patients Enrolled
45 Trials studying Obesity
1,621 Patients Enrolled for Obesity
Harvey G Anderson, PhDPrincipal InvestigatorUniversity of Toronto
3 Previous Clinical Trials
73 Total Patients Enrolled
3 Trials studying Obesity
73 Patients Enrolled for Obesity

Media Library

Crackers/pasta with added faba bean flour (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT02658591 — N/A
Obesity Research Study Groups: Control, Faba bean protein concentrate, Faba bean protein isolate, Faba bean flour, Faba bean starch
Obesity Clinical Trial 2023: Crackers/pasta with added faba bean flour Highlights & Side Effects. Trial Name: NCT02658591 — N/A
Crackers/pasta with added faba bean flour (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02658591 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Apr 2025